Company Overview and News
Netflix, Inc. (NASDAQ:NFLX) may be plunging 14% right now. But don’t let that faze you. There is a reason why the Street has always been cautious about investing in Netflix. Even now I can see that top analysts only have a cautiously optimistic Buy rating on NFLX. And post-plunge they are still only modelling for 4% upside potential from current levels. Netflix is still expensive full stop.
WFCNP FB C.WSA WFC.PRL NFLX WFC.PRJ GOOG WFC.PRT C.WS.B ZION WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV C.PRS WFC VFC WFC.WS C C.PRL C.PRJ C.PRK NYTAB C.PRG C.PRC JPM GOOGL C.PRPCL CGBBW PNC RTN
We sold V.F. Corporation (NYSE:VFC) just before it announced earnings on the 4th of this month. Although shares dropped post earnings to below $74 a share, trading in VFC has been robust since then, as shares have rallied well past $77 a share. In many ways, the snapback rally stands to reason, given the company actually reported both an earnings and revenue beat. In fact, despite the post earnings sell-off, there was nothing in the earnings report that potentially suggested that a cyclical top is close at hand.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washi
The expected move V.F. Corporation (NYSE:VFC) (expected trading range VFC's shares will see tomorrow when earnings are released) is about $2.5 in either direction. Obviously we will have to see the trading action today to see where VFC ends the trading day. We calculate the expected move by working out the at the money straddle (sum of the at the money call option & put option) and then multiplying this number by 0.
This month’s article marks the thirty-seventh installment in my on-going series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for “Minne(sota) ‘n Monthly.”
VIG GIS PG O.PRF OPRF CVS PRU KEY LANDP CINF AAPL EMR CAH INTC VFC PRU GLW NYSE SJM O PDCO LXP VER HRL JNJ LAND FHN FLO OHI UNH
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, April 6.
WFCNP YUM CAT WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ NKE AMZN WFC.PRP WFC.PRO WFC.PRN LULU WFC.PRY WFC.PRX WFC.PRW BBBY MCD WFC.PRV WFC VFC WFC.WS C YUMC TTWO PVH BLK JPM PNC DNKN KORS URI SBUX URBN
I’ve long been bearish on Under Armour Inc (NYSE:UA,NYSE:UAA), and for the most part I was justified in my pessimism. Since the final quarter of 2015, Under Armour stock personified the unmitigated disaster. As I previously warned, UA kept falling and falling. Still, I will give credit where it’s due: the sports apparel maker is so far the surprise hit of 2018.
VFC UA NKE UAA AAPL
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to VFC / V.F. Corp. on message board site Silicon Investor.
as of ET